入院与入院前血清肌酐作为基线评估急性内科入院患者急性肾损伤发生率及结局的影响
本研究在2436例急性内科入院患者中比较了以入院前7-365天平均血清肌酐(AKIpre)和入院时血清肌酐(AKIadm)为基线定义急性肾损伤(AKI)的发生率及与全因死亡的关系。中位随访47.70个月,两种定义下AKI发生率无差异(12.5% vs 12.2%,P=0.695),但诊断的患者集合仅中度一致(Kappa=0.596);两种AKI定义均与30天、1年和4年全因死亡风险升高独立相关,且低于AKI诊断阈值的轻微肌酐升高亦与死亡风险增加相关。
要点
- 入院前与入院时肌酐定义AKI的发生率相似,但诊断的患者集合仅中度一致。
- 两种定义下的AKI均与30天、1年和4年全因死亡风险升高独立相关。
- 低于AKI诊断阈值的轻微血清肌酐升高亦与随访期间死亡风险增加相关。
核心结论
- 以入院前或入院时血清肌酐为基线定义的AKI发生率相似,但诊断的是不同的患者集合。
- 即使血清肌酐轻微升高、未达到AKI分类标准,也与全因死亡风险增加相关。
研究设计与样本
- 研究纳入2436例入住三级医院的急性内科患者,中位随访47.70个月(四分位距18.20个月)。
- AKI发生率和严重程度依据KDIGO-AKI指南定义,随访数据来自医院 Episode Statistics 和 Office of National Statistics。
- 死亡结局评估分为短期(30天)、中期(1年)和长期(4年)三个时段。
主要发现
- 使用AKIpre和AKIadm定义的AKI发生率无差异(12.5% vs 12.2%;P=0.695),AKI严重程度亦无差异(P=0.261)。
- 两种定义之间的一致性为中度(Kappa统计量=0.596,P<0.001)。
- AKIpre或AKIadm患者在所有随访时段的全因死亡率均高于无AKI患者。
- 完全调整回归分析中,AKIpre(HR=2.226,95%CI 1.140-4.347;P=0.027)和AKIadm(HR=2.105,95%CI 1.090-4.064;P=0.027)均与30天死亡率相关,1年和4年结果相似。
- 从入院前肌酐升高>4.00 μmol/L和>6.06%,或从入院时肌酐升高>6.00 μmol/L和>17.24%,与随访期间死亡风险增加相关。
临床怎么用
- 临床可采用入院前或入院时血清肌酐作为基线评估AKI,但需注意两者诊断的患者集合不同。
- 应关注未达到AKI诊断标准的轻微血清肌酐升高,因其亦与死亡风险增加相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute kidney injury (AKI) in hospital-admitted patients is a common complication associated with increased mortality. The diagnosis of AKI relies on the ascertainment of peak increase in serum creatinine (SCr). This study evaluated the incidence of AKI using the increase from mean 7-365 days pre-admission (AKIpre) and admission (AKIadm) SCr levels, and examined the associations of AKI and changes in SCr levels with all-cause mortality. METHODS: A total of 2436 patients admitted to a tertiary hospital were recruited and followed-up for a median of 47.70 (interquartile range 18.20) months. AKI incidence and severity were defined according to the Kidney Disease: Improving Global Outcomes-AKI Guidelines. Follow-up data were collected from the Hospital Episode Statistics and Office of National Statistics. Mortality was evaluated during a short- (30 days), mid- (1 year) and long-term (4 years) period. RESULTS: No difference in the AKI rates using AKIpre and AKIadm (12.5% versus 12.2%; P = 0.695) or in the AKI severity (P = 0.261) was evident. Agreement between the two definitions was modest (Kappa-statistic = 0.596, P < 0.001). Patients with AKIpre or AKIadm had increased all-cause mortality compared with those without AKI during all follow-up periods. In fully adjusted regression analysis, AKIpre [hazard ratio (HR) = 2.226, 95% confidence interval (CI) 1.140-4.347; P = 0.027] and AKIadm (HR = 2.105, 95% CI 1.090-4.064; P = 0.027) remained associated with 30-day mortality. Results for the 1- and 4-year periods were similar. Increases of >4.00 μmol/L and >6.06% from pre-admission or >6.00 μmol/L and >17.24% from admission SCr levels presented increased mortality risk during follow-up. CONCLUSIONS: Use of admission or pre-admission SCr provides similar incidence rates, but they diagnose different sets of patients. Even minor increases in SCr, below those required for the classification of AKI, were associated with increased mortality. These findings can help the clinicians to identify patients at higher risk for adverse outcomes.
引用
- Pickup L, Loutradis C, Law JP, et al. The effect of admission and pre-admission serum creatinine as baseline to assess incidence and outcomes of acute kidney injury in acute medical admissions. Nephrol Dial Transplant. 2021. PMID: 33458773. doi:10.1093/ndt/gfaa333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。